This multicentre study, employing a randomised controlled repeated measures experimental design, will be conducted in several Portuguese institutions that provide care and support services for older adults diagnosed with mild to moderate Alzheimer's disease (AD). The primary aim is to evaluate the effects of two distinct cognitive stimulation modalities (digital vs physical/analogue). The study will assess the impact of individual cognitive stimulation on multiple domains - specifically cognitive function (with an emphasis on memory and executive function), mood, and quality of life - and investigate how institutional and territorial characteristics influence these effects, considering geographical and organisational diversity as potential moderating factors.
Age range
65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Cognitive functioning assessed through Mini-Mental State Examination (MMSE)
Timeframe: Baseline
Change in cognitive functioning assessed through Mini-Mental State Examination (MMSE)
Timeframe: 12 weeks after the baseline
Change in cognitive functioning assessed through Mini-Mental State Examination (MMSE)
Timeframe: 24 weeks after the baseline
Cognitive functioning assessed through Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-COG)
Timeframe: Baseline
Change in cognitive functioning assessed through Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-COG)
Timeframe: 12 weeks after the baseline
Change in cognitive functioning assessed through Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-COG)
Timeframe: 24 weeks after the baseline
Memory function evaluated through Memory Alteration Test (MAT)
Timeframe: Baseline
Change in memory function evaluated through Memory Alteration Test (MAT)
Timeframe: 12 weeks after the baseline
Change in memory function evaluated through Memory Alteration Test (MAT)
Timeframe: 24 weeks after the baseline
Executive functions assessed through Frontal Assessment Battery (FAB)
Timeframe: Baseline
Change in executive functions assessed through Frontal Assessment Battery (FAB)
Timeframe: 12 weeks after the baseline
Change in executive functions assessed through Frontal Assessment Battery (FAB)
Timeframe: 24 weeks after the baseline